You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIloperidone
Accession NumberDB04946
TypeSmall Molecule
GroupsApproved
DescriptionIloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase III development rights have been acquired by Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Structure
Thumb
Synonyms
1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone
4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
Fanapt
Fanapta
HP 873
Iloperidona
Iloperidonum
Zomaril
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FanaptkitoralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Fanapttablet1 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Fanapttablet10 mg/1oralVanda Pharmaceuticals Inc.2016-01-15Not applicableUs
Fanapttablet8 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Fanapttablet4 mg/1oralVanda Pharmaceuticals Inc.2015-12-15Not applicableUs
Fanapttablet2 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Fanapttablet10 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Fanapttablet8 mg/1oralVanda Pharmaceuticals Inc.2015-09-15Not applicableUs
Fanapttablet4 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Fanapttablet12 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
FanaptkitoralVanda Pharmaceuticals Inc.2015-12-01Not applicableUs
Fanapttablet6 mg/1oralNovartis Pharmaceuticals Corporation2009-10-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FiaptaNot Available
ZomarilNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIVPO7KJ050N
CAS number133454-47-4
WeightAverage: 426.4806
Monoisotopic: 426.195485567
Chemical FormulaC24H27FN2O4
InChI KeyInChIKey=XMXHEBAFVSFQEX-UHFFFAOYSA-N
InChI
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
IUPAC Name
1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one
SMILES
COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzisoxazoles. These are aromatic compounds containing a benzene ring fused to an isoxazole ring. Isoxazole is five-membered ring with three carbon atoms, and an oxygen atom next to a nitrogen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzisoxazoles
Sub ClassNot Available
Direct ParentBenzisoxazoles
Alternative Parents
Substituents
  • Benzisoxazole
  • Acetophenone
  • Methoxybenzene
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aralkylamine
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Oxazole
  • Isoxazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationTreatment of acute schizophrenia.
PharmacodynamicsIloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors.
Mechanism of actionIloperidone is a dopamine D2 and 5-HT2A receptor antagonist and acts as a neuroleptic agent.
Related Articles
AbsorptionWell absorbed from the GI tract and Cmax is reached within 2-4 hours. Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion.
Volume of distribution

Apparent Vd = 1340-2800 L

Protein binding95% of iloperidone is bound to protein. Percent bound is not altered by renal or hepatic impairment or combination therapy with ketoconazole.
Metabolism

Iloperidone is hepatically metabolized by cytochrome enzymes which mediates O-dealkylation (CYP3A4), hydroxylation (CYP2D6), and decarboxylation/reduction processes. Metabolites formed are P89, P95, and P88. The minor metabolite is P89, whereas P95 and P88 are the major ones. The affinity of the iloperidone metabolite P88 is generally equal or less than that of the parent compound. In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NEα1A, NEα1B, NEα1D, and NEα2C receptors (Ki values of 4.7, 2.7, 8.8 and 4.7 nM respectively).

Route of eliminationRenal (in which <1% of iloperidone is excreted unchanged).
Half lifeThe observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.
Clearance

Apparent clearance (clearance/bioavilability) = 47-102 L/h.

ToxicityCommonly observed adverse reactions (incidence ≥5% and two-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9848
Caco-2 permeable+0.5513
P-glycoprotein substrateSubstrate0.6668
P-glycoprotein inhibitor IInhibitor0.8242
P-glycoprotein inhibitor IIInhibitor0.9268
Renal organic cation transporterInhibitor0.5726
CYP450 2C9 substrateNon-substrate0.9051
CYP450 2D6 substrateSubstrate0.892
CYP450 3A4 substrateSubstrate0.7409
CYP450 1A2 substrateNon-inhibitor0.6111
CYP450 2C9 inhibitorNon-inhibitor0.5061
CYP450 2D6 inhibitorNon-inhibitor0.886
CYP450 2C19 inhibitorInhibitor0.6257
CYP450 3A4 inhibitorInhibitor0.6777
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9008
Ames testNon AMES toxic0.6314
CarcinogenicityNon-carcinogens0.8699
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6563
hERG inhibition (predictor II)Inhibitor0.7945
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kitoral
Tabletoral1 mg/1
Tabletoral10 mg/1
Tabletoral12 mg/1
Tabletoral2 mg/1
Tabletoral4 mg/1
Tabletoral6 mg/1
Tabletoral8 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8586610 No2007-11-022027-11-02Us
US8652776 No2010-08-312030-08-31Us
US8999638 No2010-10-282030-10-28Us
US9072742 No2011-01-162031-01-16Us
US9074254 No2011-12-282031-12-28Us
US9074255 No2010-12-172030-12-17Us
US9074256 No2011-02-102031-02-10Us
US9138432 No2005-09-302025-09-30Us
US9157121 No2010-04-052030-04-05Us
USRE39198 No1996-11-152016-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0304 mg/mLALOGPS
logP4.26ALOGPS
logP3.22ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)16.14ChemAxon
pKa (Strongest Basic)7.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area64.8 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity116.65 m3·mol-1ChemAxon
Polarizability46.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5364866
General References
  1. Strupczewski JT, Bordeau KJ, Chiang Y, Glamkowski EJ, Conway PG, Corbett R, Hartman HB, Szewczak MR, Wilmot CA, Helsley GC: 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem. 1995 Mar 31;38(7):1119-31. [PubMed:7707315 ]
  2. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630 ]
  3. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482 ]
  4. Hesselink JM: Iloperidone (Hoechst Marion Roussel Inc). IDrugs. 1999 Jun;2(6):584-90. [PubMed:16127622 ]
  5. Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M: The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther. 1995 Sep;274(3):1404-13. [PubMed:7562515 ]
  6. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
  7. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370 ]
External Links
ATC CodesN05AX14
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (352 KB)
MSDSDownload (480 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Iloperidone.
AbirateroneThe serum concentration of Iloperidone can be increased when it is combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Iloperidone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Iloperidone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Iloperidone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Iloperidone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Iloperidone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Iloperidone.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Iloperidone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Iloperidone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Iloperidone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Iloperidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Iloperidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Iloperidone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Iloperidone.
AmantadineAmantadine may increase the QTc-prolonging activities of Iloperidone.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Iloperidone.
AmisulprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Iloperidone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Iloperidone.
AmoxapineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Iloperidone.
AmphetamineIloperidone may decrease the stimulatory activities of Amphetamine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Iloperidone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Iloperidone.
AprepitantThe serum concentration of Iloperidone can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Iloperidone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Iloperidone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Iloperidone.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Iloperidone.
ArtemetherIloperidone may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Iloperidone.
AsenapineIloperidone may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Atazanavir.
AtomoxetineThe metabolism of Iloperidone can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Iloperidone.
AzelastineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Iloperidone.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Iloperidone.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Iloperidone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Iloperidone.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Iloperidone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Iloperidone.
BenzphetamineIloperidone may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Iloperidone.
BetaxololThe metabolism of Iloperidone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Iloperidone can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Boceprevir.
BortezomibThe metabolism of Iloperidone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Iloperidone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Iloperidone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
BrimonidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloperidone.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Iloperidone.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Iloperidone.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Iloperidone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloperidone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iloperidone.
BupropionThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Iloperidone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Iloperidone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Iloperidone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Iloperidone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Iloperidone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Iloperidone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Iloperidone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iloperidone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Iloperidone.
CaffeineThe metabolism of Iloperidone can be decreased when combined with Caffeine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iloperidone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Iloperidone.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Iloperidone.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Iloperidone.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Iloperidone.
CelecoxibThe metabolism of Iloperidone can be decreased when combined with Celecoxib.
CeritinibCeritinib may increase the QTc-prolonging activities of Iloperidone.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Iloperidone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Iloperidone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iloperidone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Iloperidone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Iloperidone.
ChloroquineChloroquine may increase the QTc-prolonging activities of Iloperidone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iloperidone.
ChlorphentermineIloperidone may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Iloperidone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Iloperidone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Iloperidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Iloperidone.
CholecalciferolThe metabolism of Iloperidone can be decreased when combined with Cholecalciferol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Iloperidone.
CimetidineThe metabolism of Iloperidone can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Iloperidone.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Iloperidone.
CisaprideCisapride may increase the QTc-prolonging activities of Iloperidone.
CitalopramCitalopram may increase the QTc-prolonging activities of Iloperidone.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Iloperidone.
ClemastineThe metabolism of Iloperidone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Iloperidone.
ClobazamThe metabolism of Iloperidone can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Iloperidone.
ClomipramineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Iloperidone.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Iloperidone.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Iloperidone.
ClotrimazoleThe metabolism of Iloperidone can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Iloperidone.
ClozapineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clozapine.
CobicistatThe serum concentration of Iloperidone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Iloperidone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Iloperidone.
ConivaptanThe serum concentration of Iloperidone can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Iloperidone.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Iloperidone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.
CyclosporineThe metabolism of Iloperidone can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Iloperidone.
Cyproterone acetateThe serum concentration of Iloperidone can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Iloperidone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Iloperidone.
DapoxetineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dapoxetine.
DarifenacinThe metabolism of Iloperidone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Iloperidone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Iloperidone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Iloperidone can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Iloperidone.
DelavirdineThe metabolism of Iloperidone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Iloperidone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Iloperidone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Iloperidone.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iloperidone.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Iloperidone.
DexamethasoneThe serum concentration of Iloperidone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Iloperidone.
DextroamphetamineIloperidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Iloperidone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Iloperidone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Iloperidone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Iloperidone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Iloperidone.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Iloperidone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iloperidone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Iloperidone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Iloperidone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Iloperidone.
DiltiazemThe metabolism of Iloperidone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iloperidone.
DiphenhydramineThe metabolism of Iloperidone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iloperidone.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Iloperidone.
DisulfiramThe metabolism of Iloperidone can be decreased when combined with Disulfiram.
DofetilideDofetilide may increase the QTc-prolonging activities of Iloperidone.
DolasetronDolasetron may increase the QTc-prolonging activities of Iloperidone.
DomperidoneDomperidone may increase the QTc-prolonging activities of Iloperidone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Iloperidone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Iloperidone.
DoxycyclineThe metabolism of Iloperidone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
DoxylamineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Iloperidone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
DronedaroneDronedarone may increase the QTc-prolonging activities of Iloperidone.
DroperidolDroperidol may increase the QTc-prolonging activities of Iloperidone.
DroperidolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Iloperidone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Iloperidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Iloperidone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Iloperidone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Iloperidone.
EfavirenzThe serum concentration of Iloperidone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Iloperidone is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Iloperidone.
EliglustatIloperidone may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Iloperidone.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iloperidone.
EnzalutamideThe serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Iloperidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Iloperidone.
EribulinEribulin may increase the QTc-prolonging activities of Iloperidone.
ErythromycinErythromycin may increase the QTc-prolonging activities of Iloperidone.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Iloperidone.
Eslicarbazepine acetateThe serum concentration of Iloperidone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Iloperidone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Iloperidone.
EthanolIloperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Iloperidone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iloperidone.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Iloperidone.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Iloperidone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Iloperidone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Iloperidone.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Iloperidone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Iloperidone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Iloperidone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Iloperidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Iloperidone.
EtravirineThe serum concentration of Iloperidone can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Iloperidone.
EzogabineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Iloperidone.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Iloperidone.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Iloperidone.
FenfluramineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iloperidone.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Iloperidone.
FingolimodFingolimod may increase the QTc-prolonging activities of Iloperidone.
FlecainideFlecainide may increase the QTc-prolonging activities of Iloperidone.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Iloperidone.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Iloperidone.
FluconazoleThe metabolism of Iloperidone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Iloperidone.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Iloperidone.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Iloperidone.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Iloperidone.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Iloperidone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Iloperidone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Iloperidone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Iloperidone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Iloperidone.
FluvoxamineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Iloperidone.
FosamprenavirThe metabolism of Iloperidone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Iloperidone can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Iloperidone.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Iloperidone.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Iloperidone.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Iloperidone.
Fusidic AcidThe serum concentration of Iloperidone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iloperidone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Iloperidone is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Iloperidone.
GalantamineGalantamine may increase the QTc-prolonging activities of Iloperidone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Iloperidone.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Iloperidone.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Iloperidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Iloperidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Iloperidone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Iloperidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Iloperidone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Iloperidone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Iloperidone.
GoserelinGoserelin may increase the QTc-prolonging activities of Iloperidone.
GranisetronGranisetron may increase the QTc-prolonging activities of Iloperidone.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Iloperidone.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Iloperidone.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Iloperidone.
HaloperidolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Iloperidone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Iloperidone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Iloperidone.
HistrelinHistrelin may increase the QTc-prolonging activities of Iloperidone.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Iloperidone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Iloperidone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.
Hydroxyamphetamine hydrobromideIloperidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
HydroxyzineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Iloperidone.
IbutilideIbutilide may increase the QTc-prolonging activities of Iloperidone.
IdelalisibThe serum concentration of Iloperidone can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Iloperidone can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Iloperidone.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Iloperidone.
IndalpineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Iloperidone.
IndinavirThe metabolism of Iloperidone can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Iloperidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Iloperidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Iloperidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Iloperidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Iloperidone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Iloperidone.
IsavuconazoniumThe metabolism of Iloperidone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Iloperidone.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Iloperidone.
IsoniazidThe metabolism of Iloperidone can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Iloperidone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Iloperidone.
IvacaftorThe serum concentration of Iloperidone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Iloperidone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Iloperidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Iloperidone.
KetoconazoleThe metabolism of Iloperidone can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iloperidone.
LapatinibLapatinib may increase the QTc-prolonging activities of Iloperidone.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Iloperidone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Iloperidone.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Iloperidone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Iloperidone.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Iloperidone.
LevocetirizineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Iloperidone.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Iloperidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iloperidone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iloperidone.
LidocaineThe metabolism of Iloperidone can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Iloperidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Iloperidone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Iloperidone.
LisdexamfetamineIloperidone may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Iloperidone.
LithiumThe risk or severity of adverse effects can be increased when Iloperidone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Iloperidone.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Iloperidone.
LopinavirLopinavir may increase the QTc-prolonging activities of Iloperidone.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Iloperidone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Iloperidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Iloperidone.
LovastatinThe metabolism of Iloperidone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Iloperidone.
Lu AA21004The risk or severity of adverse effects can be increased when Iloperidone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Iloperidone can be increased when it is combined with Luliconazole.
LumefantrineIloperidone may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iloperidone.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Iloperidone.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Iloperidone.
MefloquineMefloquine may increase the QTc-prolonging activities of Iloperidone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Iloperidone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Iloperidone.
MephentermineIloperidone may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Iloperidone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.
MequitazineIloperidone may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Iloperidone.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.
MethadoneMethadone may increase the QTc-prolonging activities of Iloperidone.
MethadoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Iloperidone.
MethamphetamineIloperidone may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Iloperidone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Iloperidone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Iloperidone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Iloperidone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Iloperidone.
MethsuximideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Iloperidone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.
MetoprololThe metabolism of Iloperidone can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Iloperidone.
MetyrosineIloperidone may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Iloperidone.
MexiletineThe metabolism of Iloperidone can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Iloperidone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Iloperidone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Iloperidone.
MilnacipranThe risk or severity of adverse effects can be increased when Iloperidone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
MirabegronThe metabolism of Iloperidone can be decreased when combined with Mirabegron.
MirtazapineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Iloperidone.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Iloperidone.
MitotaneThe serum concentration of Iloperidone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Iloperidone.
ModafinilThe serum concentration of Iloperidone can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Iloperidone.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Iloperidone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Iloperidone.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Iloperidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
NabiloneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Nabilone.
NafcillinThe serum concentration of Iloperidone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iloperidone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Iloperidone.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Iloperidone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Iloperidone.
NelfinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir.
NetupitantThe serum concentration of Iloperidone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Iloperidone can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Iloperidone can be decreased when combined with Nicardipine.
NicotineThe metabolism of Iloperidone can be decreased when combined with Nicotine.
NilotinibNilotinib may increase the QTc-prolonging activities of Iloperidone.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Iloperidone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Iloperidone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Iloperidone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Iloperidone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Iloperidone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Iloperidone.
OctreotideOctreotide may increase the QTc-prolonging activities of Iloperidone.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Iloperidone.
OlanzapineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Olanzapine.
OlaparibThe metabolism of Iloperidone can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Iloperidone.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Iloperidone.
OndansetronOndansetron may increase the QTc-prolonging activities of Iloperidone.
OndansetronThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Iloperidone.
OrphenadrineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Iloperidone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Iloperidone.
OsimertinibThe serum concentration of Iloperidone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Iloperidone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Iloperidone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Iloperidone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iloperidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iloperidone.
OxytocinOxytocin may increase the QTc-prolonging activities of Iloperidone.
PalbociclibThe serum concentration of Iloperidone can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Iloperidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Iloperidone.
ParaldehydeIloperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Iloperidone.
ParoxetineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Iloperidone.
PazopanibPazopanib may increase the QTc-prolonging activities of Iloperidone.
Peginterferon alfa-2bThe serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Iloperidone.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Iloperidone.
PerampanelThe risk or severity of adverse effects can be increased when Iloperidone is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Iloperidone.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Iloperidone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Iloperidone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Iloperidone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Iloperidone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Iloperidone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Iloperidone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Iloperidone.
PhentermineIloperidone may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Iloperidone.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Iloperidone.
PimozidePimozide may increase the QTc-prolonging activities of Iloperidone.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Iloperidone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Iloperidone.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Iloperidone.
PizotifenThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.
PosaconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Posaconazole.
PramipexoleIloperidone may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Iloperidone.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Iloperidone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Iloperidone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Iloperidone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Iloperidone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Iloperidone.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Iloperidone.
ProcainamideProcainamide may increase the QTc-prolonging activities of Iloperidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Iloperidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Iloperidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.
PromazinePromazine may increase the QTc-prolonging activities of Iloperidone.
PromazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Iloperidone.
PropafenonePropafenone may increase the QTc-prolonging activities of Iloperidone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Iloperidone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Iloperidone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Iloperidone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Iloperidone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Iloperidone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Iloperidone.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Iloperidone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Iloperidone.
QuinidineQuinidine may increase the QTc-prolonging activities of Iloperidone.
QuinineQuinine may increase the QTc-prolonging activities of Iloperidone.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Iloperidone.
RanolazineThe metabolism of Iloperidone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Iloperidone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iloperidone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Iloperidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Iloperidone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Iloperidone.
RifabutinThe metabolism of Iloperidone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Iloperidone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Iloperidone can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Iloperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Iloperidone.
RitonavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Iloperidone.
RolapitantThe metabolism of Iloperidone can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Iloperidone.
RopiniroleIloperidone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Iloperidone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Iloperidone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Iloperidone.
RotigotineIloperidone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Iloperidone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Iloperidone.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Iloperidone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Iloperidone.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Iloperidone.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Iloperidone.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Iloperidone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Iloperidone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Iloperidone.
SertralineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Iloperidone.
SildenafilThe metabolism of Iloperidone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Iloperidone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Iloperidone can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Iloperidone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Iloperidone.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Iloperidone.
SorafenibSorafenib may increase the QTc-prolonging activities of Iloperidone.
SotalolSotalol may increase the QTc-prolonging activities of Iloperidone.
St. John's WortThe serum concentration of Iloperidone can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Iloperidone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Iloperidone.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Iloperidone.
SulpirideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Iloperidone.
SunitinibSunitinib may increase the QTc-prolonging activities of Iloperidone.
SuvorexantThe risk or severity of adverse effects can be increased when Iloperidone is combined with Suvorexant.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Iloperidone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iloperidone.
TasimelteonThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Iloperidone.
TelaprevirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Iloperidone.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Iloperidone.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Iloperidone.
TenofovirThe metabolism of Iloperidone can be decreased when combined with Tenofovir.
TerbinafineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Iloperidone.
TeriflunomideThe serum concentration of Iloperidone can be decreased when it is combined with Teriflunomide.
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Iloperidone.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Iloperidone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Iloperidone.
ThalidomideIloperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Iloperidone.
TheophyllineThe metabolism of Iloperidone can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Iloperidone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Iloperidone.
ThioridazineThioridazine may increase the QTc-prolonging activities of Iloperidone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Iloperidone.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Iloperidone.
TiclopidineThe metabolism of Iloperidone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Iloperidone.
TipranavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Iloperidone.
TocilizumabThe serum concentration of Iloperidone can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Iloperidone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Iloperidone.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.
TolterodineTolterodine may increase the QTc-prolonging activities of Iloperidone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Iloperidone.
ToremifeneToremifene may increase the QTc-prolonging activities of Iloperidone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Iloperidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Iloperidone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iloperidone.
TrazodoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Iloperidone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Iloperidone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Iloperidone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Iloperidone.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Iloperidone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Iloperidone.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Iloperidone.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Iloperidone.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Iloperidone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Iloperidone.
VandetanibIloperidone may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Iloperidone.
VemurafenibIloperidone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Iloperidone.
VerapamilThe metabolism of Iloperidone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Iloperidone.
VilanterolVilanterol may increase the QTc-prolonging activities of Iloperidone.
VilazodoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Iloperidone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Iloperidone.
VoriconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Iloperidone.
VortioxetineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Iloperidone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Iloperidone.
ZiconotideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Iloperidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Iloperidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Iloperidone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Iloperidone.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iloperidone.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Iloperidone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Iloperidone.
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Iloperidone.
Food Interactions
  • Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95.
  • Can be taken with or without meals

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630 ]
  2. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630 ]
  2. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
  2. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
  2. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on September 29, 2016 02:26